Arrowhead Pharmaceuticals Inc (ARWR)
Rating suspended since 2026-09-29 — valuation input under review. The rating, price target and expected return are withheld until the name is re-valued; the research on the report page predates the review.
Model history: across 478 scored pre-registered anchors (of 480), the direction implied by our targets has been right 55.2% of the time, above the 50% a coin flip would give. Treat the expected return as a distribution estimate, not a point forecast. This name's record ↓ · full record.
General research — not personal financial advice · full disclosures in Part 9 below · How to read this card
Contents — superseded report
Superseded historical output — do not useThis report was published before its rating was suspended on 2026-09-29. Every rating, price target, expected return, scenario value and chart inside it is the withdrawn output, kept unchanged for the record. It is not current research and it is not a recommendation.Show the superseded report
Investment Committee Summary
| Rating | SELL |
| Internal 5-tier | STRONG SELL |
| Classification · conviction | mature cash generator · high |
| Evidence | 7/8 load-bearing inputs sourced — missing: Capex |
| Triangulated fair value | $19.58 (-68% vs spot · triangulated FV) |
| 12-mo scenario PWEV | $21.33 (-65% vs spot · 12m PWEV) |
| Next catalyst | 2026-11-24 — Quarterly earnings |
| Primary thesis-break | FY revenue ($B) < 0.6 (next reported fiscal year) |
Decision detail — rating tables & Research OS strip
Rating: SELL
Internal 5-tier: STRONG SELL · mature cash generator · analyst conviction: high
| Metric | Value |
|---|---|
| Current Price | $60.73 |
| Triangulated Fair Value | $19.58 (-68% vs spot · triangulated FV) |
| 12-mo Scenario PWEV | $21.33 (-65% vs spot · 12m PWEV) |
| Forward P/E | 94.9x |
| Market Cap | $9B |
| 52-Week Range | $34.61–$95.49 (intraday high and low over the trailing 52 weeks of the stock's own daily bars) |
EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).
Methodology: Valuation triangulated across four weighted anchors — an intrinsic DCF, a scenario-weighted PWEV, a Monte Carlo median (Student-t + regime switching) and a peer P/E re-rate. Anchors are blended at fixed declared weights, each counted separately; the Monte Carlo, the scenario PWEV and the DCF's exit-multiple terminal all rest on the same base multiple, so where they agree it is partly by construction — not independent corroboration. Figures reconciled to Alpha Vantage 2026-10-12. Each chart below sits with the part of the thesis it evidences.
General research, published identically to every reader. Not personal financial advice. Figures as of the analysis date; verify before acting.
Decision Support — Research OS jump to detail ↓
| Research conviction | Exp. return (1y) | Rules stance | Next catalyst |
|---|---|---|---|
| 35.7/100 (3rd pct) | -64% 1yr expected | Hold | 42d — Quarterly earnings |
Research rating: SELL · Tactical / decision-rule stance: Hold — the stance is what the model's 6 machine-checked decision rules read on this name, held by hysteresis against the last published stance; the rating is the valuation verdict. They may diverge; the rules are set out in the Decision Rules section below.
Full breakdown — conviction components, probability-return distribution, decision rules, factor & portfolio interaction and the catalyst timeline — in the Decision Support sections below. Model output for research; not personal financial advice.
📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.
Recommendation: SELL
Defensive: rating SELL; triangulated fair value $19.58 (-68% vs spot) — the risk/reward is skewed to the downside on P/E Multiple. The debate is P/E Multiple — fundamentally a multiple/regime call.
Investment Thesis
The bull case — 'Bull — Blockbuster / Pipeline Re-Rate' (8% weight) — targets $38.50, -37% vs spot. It needs the multiple to hold or expand.
The dashboard below is the whole argument on one page: spot ($60.73) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
The structural case — 'Structural — Patent Cliff (LOE) / IRA Pricing Erosion' (20%) — targets $9.57, -84% vs spot. This sits below the 52-week low — a genuine structural impairment, not a mild pullback.
Key Debate
P/E Multiple explains 93% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.
What the Market Is Pricing In
Consensus forward EPS is -4.93, so the current price implies no earnings multiple to compare against (the peer median forward P/E is 18.6×). The house DCF sits 67% below spot, so the market is pricing in more than the house case — roughly 10.1pp of revenue CAGR.
Variant perception: the house view is below-consensus, and the thesis is primarily growth-driven.
| Metric | Consensus | House | Importance |
|---|---|---|---|
| Revenue | 0.3 | 0.6 | High |
| EPS | -4.9 | 0.6 | Medium |
| Target price | 107.2 | 21.3 | Medium |
Scenario Analysis
The scenario tree spans a structural 'Structural — Patent Cliff (LOE) / IRA Pricing Erosion' downside ($9.57) to a 'Bull — Blockbuster / Pipeline Re-Rate' bull case ($38.50); the probability-weighted blend (PWEV $21.33) is -65% versus spot.
| Scenario | Probability | Target | Return vs spot |
|---|---|---|---|
| Structural — Patent Cliff (LOE) / IRA Pricing Erosion | 20% | $9.57 | -84% |
| Pipeline Setback / Pricing Pressure | 17% | $16.26 | -73% |
| Base — Pipeline Offsets LOE | 35% | $22.58 | -63% |
| Growth — Launch / Indication Expansion | 20% | $30.49 | -50% |
| Bull — Blockbuster / Pipeline Re-Rate | 8% | $38.50 | -37% |
| Probability-Weighted (PWEV, after SBC dilution) | — | $21.33 | -65% |
SBC charge: scenario targets are gross per-share prices; the PWEV is reduced by one year of stock-based-compensation dilution (2.0% of shares, on SBC ≈ 8% of revenue), trimming the gross PWEV of $21.76 to $21.33 (-2.0%). SBC is charged once, as dilution — never also deducted from FCF.
Scenario rationale — the driver path behind every target:
- Structural — Patent Cliff (LOE) / IRA Pricing Erosion (20%, $9.57). Structural impairment — patent cliff (LOE) / IRA pricing erosion: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
- Pipeline Setback / Pricing Pressure (17%, $16.26). Cyclical downturn — drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory weakens for 1–2 years before normalising.
- Base — Pipeline Offsets LOE (35%, $22.58). Mid-cycle — normalised drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory; disciplined capital allocation; steady returns.
- Growth — Launch / Indication Expansion (20%, $30.49). Upside — pipeline launches + indication expansion lifts earnings above mid-cycle; the multiple expands modestly.
- Bull — Blockbuster / Pipeline Re-Rate (8%, $38.50). Upside tail — sustained tight conditions or a structural re-rate on pipeline launches + indication expansion.
Valuation Triangulation
Four weighted anchors — an intrinsic dcf, a scenario-weighted pwev, a monte carlo median (student-t + regime switching) and a peer p/e re-rate — read them with their basis in mind. The Monte Carlo, the scenario PWEV, any DCF's exit-multiple terminal and any peer re-rate key off a market multiple, so they are not independent; only a DCF's explicit-period cash flows are multiple-free, and its terminal usually carries most of its value. The discipline is to read the spread, not to treat four numbers as four independent votes.
| Method | Basis | Fair Value | vs Spot | Weight in this name's blend |
|---|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $19.57 | -68% | 18% (declared 15%) |
| Peer P/E re-rate | multiple | $11.90 | -80% | 10% |
| Peer EV/Revenue re-rate | multiple | $25.92 | -57% | 0% — cross-check only |
| Scenario PWEV | multiple | $21.33 | -65% | 30% (declared 25%) |
| DCF (5-year + exit-multiple terminal) | cash flow + terminal × | $20.23 | -67% | 42% (declared 35%) |
| Triangulated (weighted) | — | $19.58 | -68% | 100% |
The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts is not computed, so 15% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way. The company-lever row in the Sensitivity section is an illustrative EBIT × multiple value, not a sum-of-parts anchor.
Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.
Monte Carlo — the outcome distribution
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $19.57 and 0% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (93% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.
DCF — explicit-period cash flows with an exit-multiple terminal
A 5-year cash-flow path discounted at a WACC of 8.5%, plus a terminal value of final-year FCF × 29.0x — a terminal multiple equal to 0.85 × the base multiple that the Monte Carlo and the scenario tree also use → $20.23. The terminal value is 84% of enterprise value, so this anchor moves with the multiple assumption. The heaviest anchor in this blend (42%); because its terminal is a market multiple, it is not independent of the multiple-driven anchors.
Peer benchmarking — relative value
Against its 4 peers in the same GICS sub-industry, re-rating to their median forward multiple (P/E 18.6x) implies $11.90. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 10% so market sentiment does not set the fair value.
Across all anchors the spread is 69% of the median — wide (genuine disagreement — the blend carries low valuation confidence).
Sensitivity
DCF/share — WACC × terminal multiple
| WACC ＼ Term× | 20.3x | 24.6x | 29.0x | 33.3x | 37.7x |
|---|---|---|---|---|---|
| 6.5% | $17.01 | $19.38 | $21.80 | $24.17 | $26.60 |
| 7.5% | $16.42 | $18.68 | $20.99 | $23.25 | $25.57 |
| 8.5% | $15.86 | $18.02 | $20.23 | $22.39 | $24.59 |
| 9.5% | $15.33 | $17.39 | $19.50 | $21.56 | $23.67 |
| 10.5% | $14.82 | $16.79 | $18.81 | $20.78 | $22.80 |
DCF/share — revenue CAGR Δ × model op-margin Δ (Δ applied to the DCF's house margin path)
| CAGRΔ ＼ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $15.74 | $17.06 | $18.38 | $19.70 | $21.02 |
| -1.5pp | $16.45 | $17.87 | $19.28 | $20.69 | $22.10 |
| +0.0pp | $17.20 | $18.71 | $20.23 | $21.74 | $23.25 |
| +1.5pp | $17.99 | $19.60 | $21.22 | $22.84 | $24.46 |
| +3.0pp | $18.81 | $20.54 | $22.27 | $24.00 | $25.72 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Model op margin ±3pp | $17.00 | $23.00 | $6.00 |
| Terminal × ±15% | $18.00 | $22.00 | $4.00 |
| Revenue CAGR ±3pp | $18.00 | $22.00 | $4.00 |
| Capex intensity ±15% | $19.00 | $21.00 | $2.00 |
| WACC ±1pp | $19.00 | $21.00 | $1.00 |
Company lever — value at the base multiple vs Biopharma multiple (base 34.0x)
| Multiple | 23.8x | 28.9x | 34.0x | 39.1x | 44.2x |
|---|---|---|---|---|---|
| Value at the base multiple (EBIT × multiple; illustrative, not a blend anchor) | $24.00 | $29.00 | $34.00 | $38.00 | $43.00 |
Illustrative: segment EBIT × multiple, plus net cash, over basic shares — it does not enter the triangulated fair value.
Peer Quality & Weighting
| Peer | Fwd P/E | Growth | Op margin | Quality | Weight cap |
|---|---|---|---|---|---|
| UTHR | 19.5× | 4% | 42% | broad | 25% |
| NBIX | 24.1× | 4% | 23% | broad | 25% |
| EXEL | 17.7× | 4% | 41% | broad | 25% |
| BMRN | 12.0× | 4% | 18% | broad | 25% |
Quality-weighted forward P/E: 18.3× (simple median 18.6×). Direct peers count 100%, segment 50%, broad 25%.
Valuation-anchor screen: DCF (Gordon) (excluded (>3× or <0.3× spot)); Peer (fwd P/E) (excluded (>3× or <0.3× spot)). Anchor median 19.6. Extreme/excluded anchors carry no headline weight.
Historical-range cross-check: 52-week range $34.61–$95.49, centre $57.50 (-5% vs spot); spot sits at the 43rd percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.
Risk / Reward & Margin of Safety
| Metric | Value |
|---|---|
| Upside to triangulated FV (FV ÷ price − 1) | $19.58 (-68% vs spot · triangulated FV) |
| Downside to lowest scenario (Structural — Patent Cliff (LOE) / IRA Pricing Erosion) | $9.57 (-84% vs spot · bear scenario) |
| Reward-to-risk ratio | withheld — the triangulated FV is at or below spot, so there is no reward leg to divide by the risk leg |
| Discount to fair value (1 − price ÷ FV) | -210% |
| P(price > spot) — Monte Carlo | 0% |
That ratio is (triangulated FV ÷ price − 1) ÷ (1 − 'Structural — Patent Cliff (LOE) / IRA Pricing Erosion' target ÷ price). 'Structural — Patent Cliff (LOE) / IRA Pricing Erosion' ($9.57, probability 20%) is the lowest-target scenario in the tree, taken gross of SBC dilution. With a leg missing the ratio is withheld rather than computed from a magnitude. Bull case (Bull — Blockbuster / Pipeline Re-Rate): $38.50.
Company Overview & Business Model
Arrowhead Pharmaceuticals Inc — HEALTHCARE · BIOTECHNOLOGY. Arrowhead Pharmaceuticals, Inc. develops drugs for the treatment of intractable diseases in the United States. The company is headquartered in Pasadena, California.
Company description as supplied by Alpha Vantage; not checked against the company's filings.
How it makes money.
| Segment | Rev mix | Growth | Model op margin† | Key driver |
|---|---|---|---|---|
| Biopharma | 100% | +4% | 21% | drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory |
† Model margin = gross margin − the opex ratio calibrated so the Monte Carlo median EPS meets the EPS target; it is not a reported operating margin.
Reported operating margin (GAAP): 11.8% for the fiscal year ended 2025-09-30; -33.8% TTM to 2026-06-30 (Alpha Vantage INCOME_STATEMENT).
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Model op margin† | Model EBIT | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|---|
| Biopharma | $0.6B | 100% | 4% | 21% | $0.1B | 34.0x | 6% | ESTIMATE |
| † Model EBIT = revenue × the model margin, i.e. gross margin less the opex ratio the calibration solved for to meet the EPS target — not the company's reported operating income. |
For comparison, the company's reported GAAP operating margin was 11.8% for the fiscal year ended 2025-09-30; -33.8% TTM to 2026-06-30 (Alpha Vantage INCOME_STATEMENT).
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory |
| net_debt_or_cash_b | 0.41 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.06 |
| div_yield | — |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | patent cliff (LOE) / IRA pricing erosion |
| upside | pipeline launches + indication expansion |
Industry Context — Health Care — Pharma
This name sits in the Health Care — Pharma cluster as a biopharma name. drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory. Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.
Value chain: UTHR (biopharma) · NBIX (biopharma) · JAZZ (biopharma) · EXEL (biopharma) · ELAN (biopharma) · BMRN (biopharma) · CYTK (biopharma) · ARWR (biopharma) · HALO (biopharma) · RGEN (biopharma)
| Shared state | Capex path | House view | This name implies |
|---|---|---|---|
| Patent Cliff / IRA Pricing Erosion | not stated | 37% | 37% |
| Mid-Cycle — Pipeline Offsets LOE | not stated | 35% | 35% |
| Upside — Launches / Pipeline Re-Rate | not stated | 28% | 28% |
Mapping note: name-level 'Structural — Patent Cliff (LOE) / IRA Pricing Erosion' (20%) + 'Pipeline Setback / Pricing Pressure' (17%) map to cluster Patent Cliff / IRA Pricing Erosion (37%); name-level 'Growth — Launch / Indication Expansion' (20%) + 'Bull — Blockbuster / Pipeline Re-Rate' (8%) map to cluster Upside — Launches / Pipeline Re-Rate (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.
On the cluster's key downside — Patent Cliff / IRA Pricing Erosion — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.
Structure: Shared State — The Health Care — Pharma cycle is the shared macro driver. Driver — drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory. Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).
Balance Sheet & Liquidity
| Metric | Value |
|---|---|
| Net debt | $-0.6B — net cash |
| Net debt / EBITDA | 2.76x |
| Interest coverage (EBIT / interest) | 1.6x |
| Current ratio | 4.88x |
| Lease obligations | $0.1B |
| Cash & ST investments | $0.9B |
Balance-sheet data as of 2025-09-30 (Alpha Vantage).
Capital Allocation
| Metric | Value |
|---|---|
| Free cash flow | $0.2B |
| Buybacks / dividends | $0.0B / $0.0B |
| Total shareholder yield | 0.0% |
| Payout as % of FCF | 0.0% |
| Reinvestment (capex / OCF) | 12.8% |
| SBC as % of FCF | 40.1% |
Free-Cash-Flow Quality
| Metric | Value |
|---|---|
| FCF margin | 26.2% |
| FCF conversion (FCF / net income) | 523.3% |
| FCF yield | 1.8% |
| Capex intensity (capex / revenue) | 3.8% |
| FCF − SBC (diagnostic) | $0.1B |
Accounting quality: SBC 8% of revenue; cash conversion (OCF/NI) 600% — cash-backed.
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q2): management +0.38 vs analyst floor +0.01 → delta +0.37 (n=25 mgmt / 15 Q&A; 40th pctile across the S&P book, z -0.3).
Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q2 | +0.38 | +0.01 | +0.37 |
| 2026Q1 | +0.47 | +0.00 | +0.47 |
| 2025Q4 | +0.62 | +0.42 | +0.20 |
| 2025Q3 | +0.32 | +0.20 | +0.12 |
News (last 365d, 407 articles): avg ticker sentiment +0.26 (bullish 38% / bearish 3%)
Consensus & Market Expectations
| Reference | Value |
|---|---|
| Street target (mean) | $107 (+77% vs spot · street) |
| House target | $21.33 (-80.1% vs street) |
| Sell-side coverage | 14 analysts (SB 4 / B 9 / H 1 / S 0 / SS 0; net score 0.61) |
| Consensus FY EPS | $-4.93 (reference only — house values on EV/EBITDA) |
| Consensus FY revenue | $0.3B; house above (+79.5%) |
_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.
Catalyst Calendar
- 2026-11-24 (~43d) — Quarterly earnings — est. EPS $-1.59 (AV EARNINGS_CALENDAR)
Forecast Track Record
- EPS surprise: beat 50% of the last 8 quarters; average surprise +94.0%.
Catalyst Timeline
5 catalysts in the next 90 days (of 12 tracked). Importance 1–3; confidence 0–1.
| When | Catalyst | Type | Importance | Confidence |
|---|---|---|---|---|
| 2026-10-14 (in 1d) | September CPI | macro | ●● | 0.8 |
| 2026-10-28 (in 15d) | FOMC rate decision + press conference | macro | ●● | 0.8 |
| 2026-11-24 (in 42d) | Quarterly earnings | earnings | ●●● | 0.95 |
| 2026-12-09 (in 57d) | FOMC rate decision + SEP dot plot | macro | ●● | 0.8 |
| 2026-12-18 (in 66d) | Quarterly options-expiry cluster (3rd Friday) | opex_cluster | ● | 1.0 |
| 2027-01-27 (in 106d) | FOMC rate decision + press conference | macro | ●● | 0.8 |
| 2027-03-17 (in 155d) | FOMC rate decision + SEP dot plot | macro | ●● | 0.8 |
| 2027-03-19 (in 157d) | Quarterly options-expiry cluster (3rd Friday) | opex_cluster | ● | 1.0 |
| 2027-04-28 (in 197d) | FOMC rate decision + press conference | macro | ●● | 0.8 |
| 2027-06-09 (in 239d) | FOMC rate decision + SEP dot plot | macro | ●● | 0.8 |
| 2027-06-18 (in 248d) | Quarterly options-expiry cluster (3rd Friday) | opex_cluster | ● | 1.0 |
| 2027-09-17 (in 339d) | Quarterly options-expiry cluster (3rd Friday) | opex_cluster | ● | 1.0 |
_Sources: extended.catalysts, data/catalysts/
Decision Rules (Machine-Checked)
Stance: Hold — 0 bullish / 2 bearish / 0 caution rules triggered of 6 evaluable (0 lacked data).
| Rule | Condition | Observed | Triggered |
|---|---|---|---|
| R1-valuation-stretch | expected return vs fair value < -12 (upside_pct) |
-64.87 | YES |
| R2-valuation-opportunity | expected return vs fair value > 15 (upside_pct) |
-64.87 | no |
| R3-street-revisions | street net rating stance < -0.25 (extended.consensus.street_score) |
0.61 | no |
| R4-earnings-quality | cash conversion of earnings < 80 (extended.accounting_quality.cash_conversion_pct) |
600.0 | no |
| R5-technical-breakdown | price vs 200-day SMA < 0.85 (technicals.sma_200) |
0.84 | YES |
| R6-vol-regime-shift | IV/RV vol-risk premium > 1.4 (options_overlay.iv_rv) |
1.18 | no |
Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is what the model's own rules read on this name; it does not modify the published research rating, and it is not personal financial advice.
Reasons the Thesis Could Fail (Falsifiable)
Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:
- FY revenue ($B) < 0.6 (next reported fiscal year). (rationale withheld pending re-authoring — frozen figure or verdict)
- Probability-weighted fair value (PWEV) at the next re-run < 60.73 (any scheduled re-run). (rationale withheld pending re-authoring — frozen figure or verdict)
- Share price (close) < 9.57 (5 consecutive sessions). (rationale withheld pending re-authoring — frozen figure or verdict)
Fact / Inference / Speculation
- FACT: Spot $60.73; 52-week range $34.61–$95.49; engine rating SELL; house target $21.33 (-65%). (source: Alpha Vantage 2026-10-12, 13 October 2026)
- INFERENCE: Triangulated FV $19.58 (-68% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the DCF anchor sits below the multiple-discipline core.
- SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.
Conviction Score
Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.
35.7/100 (confidence band 26.0–45.4), 3rd percentile of 928 covered names (as of 2026-10-12). Weighted composite under config ros-1.21.0 — every component and its inputs below.
| Component | Score (0–100) | Weight | Inputs |
|---|---|---|---|
| business quality | 57 | 15% | extended.fcf_quality.fcf_margin_pct, extended.balance_sheet.net_debt_to_ebitda, extended.accounting_quality.cash_conversion_pct |
| financial strength | 29 | 10% | extended.balance_sheet.net_debt_to_ebitda, extended.balance_sheet.interest_coverage |
| valuation | 0 | 15% | upside_pct |
| growth | 40 | 10% | reconciliation.ttm_revenue_billions, reconciliation.fy_guide_revenue_billions |
| earnings visibility | 50 | 10% | extended.forecast_accuracy.eps_surprise.beat_rate_pct |
| moat | 49 | 10% | |
| technical trend (heuristic — no validation record; weight change reserved for AM-060) | 23 | 10% | technicals.rsi, technicals.sma_50, technicals.sma_200 |
| macro tailwinds | 41 | 10% | industry_context.scenario_states |
| risk profile | 39 | 10% | monte_carlo.prob_above_current, monte_carlo.p10, monte_carlo.p90, monte_carlo.median |
Score history: 39.0 → 39.0 → 39.0 → 39.4 → 39.4 → 39.4 → 39.4 → 39.4.
Probability-Weighted Return Profile
Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.
| Scenario | Probability | Target | Total return | Contribution |
|---|---|---|---|---|
| Structural — Patent Cliff (LOE) / IRA Pricing Erosion | 20% | $9.57 | -84.2% | -16.9pp |
| Pipeline Setback / Pricing Pressure | 17% | $16.26 | -73.2% | -12.4pp |
| Base — Pipeline Offsets LOE | 35% | $22.58 | -62.8% | -22.0pp |
| Growth — Launch / Indication Expansion | 20% | $30.49 | -49.8% | -10.0pp |
| Bull — Blockbuster / Pipeline Re-Rate | 8% | $38.50 | -36.6% | -2.9pp |
| Aggregate | Value |
|---|---|
| Expected return (gross, 1y) | -64.2% |
| Expected return net of SBC dilution | -64.9% |
| Outcome dispersion (σ, from MC p10–p90) | 10.5% |
| Expected Sharpe (rf 4%) | -6.47 |
| Downside expectation (prob-weighted loss branches) | -64.2% |
The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.
Expected Alpha
Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).
| Component | Value |
|---|---|
| Expected return (gross, 1y) | -64.2% |
| Risk-free rate | 4.49% (1y proxy (3m/2y midpoint; AV lacks a 1y tenor), as of 2026-10-08) |
| Beta (shrunk, 1y vs SPY) | 1.38 (as of 2026-10-12) |
| Equity risk premium | 4.5% |
| Size/liquidity premium | +100bp |
| Required return | 11.7% |
| Expected alpha | -75.9% |
| Alpha per unit risk (EA/σ) | -7.20 |
A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.
Probability Cross-Checks
Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.
| Cross-check | Ours | Comparator | Reading |
|---|---|---|---|
| Scenario spread vs options market | 14.0% (1σ) | 44.7% implied | our scenarios are far narrower than the options market prices |
| Mass above spot: scenarios vs our own MC | 0.0% | 0.0% | the two expressions of our own view agree |
| Realised scenario frequency | 32 dated anchors | — | 32 dated anchors available; realised-vs-prior comparison is now meaningful. |
Authored set: 5 scenarios, probabilities summing to 1.0, mean target $21.76.
Flagged for review: scenario spread vs the options market. A flag marks a disagreement worth understanding — it does not imply either side is wrong.
Factor Exposures
Cross-sectional percentiles over 928 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.
| Style | Percentile | Theme | Percentile | |
|---|---|---|---|---|
| Growth | 2 | AI | 84 | |
| Value | 1 | Cloud | 57 | |
| Quality | 29 | Semis | 86 | |
| Momentum | 98 | Consumer | 85 | |
| Low-Vol | 4 | Rates | 80 | |
| USD | 5 | |||
| Energy | 6 |
Market interaction: correlation vs SPY +0.39, vs QQQ +0.35 (trailing ~1y daily returns).
Rating Bridge
Rating = SELL because:
- Probability-weighted scenario value implies -65% vs spot
- Monte Carlo median implies -68% vs spot
- DCF fair value (exit-multiple terminal) implies -67% vs spot — but this is terminal-value sensitive (exit-multiple $20.23 vs Gordon $14.24, 30% apart), so it carries less weight
- Bear case (Structural — Patent Cliff (LOE) / IRA Pricing Erosion) downside is -84% vs spot
- Net: the valuation anchor itself sits 67.8% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating warrants a Sell.
Model Appendix
DCF — line items
| Year | Revenue | Op income (house path) | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $1B | $0B | $0B | $0B | $0B | $0B |
| FY+2 | $1B | $0B | $0B | $0B | $0B | $0B |
| FY+3 | $1B | $0B | $0B | $0B | $0B | $0B |
| FY+4 | $1B | $0B | $0B | $0B | $0B | $0B |
| FY+5 | $1B | $0B | $0B | $0B | $0B | $0B |
| Terminal | — | — | — | — | $0B × 29.0x | $2B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 6% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 8.5% · Σ PV(FCF) $0B + PV(terminal) $2B = EV $2B; + net cash $0.4B → equity $3B ÷ diluted shares $0.14B = $20.23/share (exit-multiple terminal).
- Gordon terminal → $14.24/share — a single-point perpetual-growth cross-check at g = 2.5% (one growth rate, not a range; it is not in the blend).
- Incremental ROIC on the forecast capex ≈ 9% vs WACC 8.5% → above WACC — the build is value-creative.
Peer set
| Peer | EV/Rev | Fwd P/E | Growth | Op margin |
|---|---|---|---|---|
| UTHR | 6.2x | 19.5x | 4% | 42% |
| NBIX | 5.2x | 24.1x | 4% | 23% |
| EXEL | 5.7x | 17.7x | 4% | 41% |
| BMRN | 3.3x | 12.0x | 4% | 18% |
| Median | 5.5x | 18.6x | — | — |
Implied prices at the peer medians: same-sub-industry median fwd P/E → $11.90; EV/Rev → $25.92.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| DCF | $20.23 | 42% | $8.47 |
| Scenario PWEV | $21.33 | 30% | $6.38 |
| Monte Carlo median | $19.57 | 18% | $3.51 |
| Peer P/E | $11.90 | 10% (part weight ×0.86 — peer sits 40%–70% from the Monte-Carlo/PWEV core) | $1.22 |
| Triangulated | — | 100% | $19.58 |
Model Calibration Caveats
Raised by the model's own checks on its run of 13 October 2026 (prices as of 2026-10-12). They concern how the model was calibrated, not the company; read the figures they touch with them in mind.
- The Monte Carlo gives only a 0% probability of the price finishing above today's; the house treats readings under 30% as a sign the downside assumptions may be too severe.
Assumption Register
| Assumption | Value | Used in | Source |
|---|---|---|---|
| WACC | 8.5% | DCF discount rate | estimate (CAPM) |
| Terminal multiple | 29× | DCF exit value | house rule (0.85 × base multiple) |
| Terminal growth | 2.5% | Gordon cross-check (single point) | estimate |
| SBC dilution | 2.0%/yr | PWEV, MC, DCF (charged once) | estimate (from SBC/rev) |
| EPS basis | consensus forward EPS (broker-adjusted, non-GAAP) | all forward P/E & scenario multiples | definition |
Sensitivity-ranked drivers (widest fair-value swing first): Model op margin ±3pp (6.0); Terminal × ±15% (4.0); Revenue CAGR ±3pp (4.0); Capex intensity ±15% (2.0); WACC ±1pp (1.0).
Inputs, Sources & Confidence
Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)
| Input | Value | Type | Source | Confidence | Used in |
|---|---|---|---|---|---|
| Revenue TTM | $0.6B | reported fact | 10-K/10-Q via AV | High | Forecast base, EV/Rev |
| FY+1 guided revenue | $0.6B | company guidance | Company guidance | Medium | Forecast, SoP |
| FY+1 guided EPS | $0.64 | company guidance | Company guidance | Medium | Forward P/E, scenarios |
| Consensus FY EPS | $-4.931 | consensus estimate | Sell-side consensus via AV | Medium | Variant perception |
| Diluted shares | 0.142B | reported fact | 10-K via AV | High | Market cap, per-share |
| Net debt / cash | $-0.553B | reported fact | Balance sheet via AV | High | EV, DCF equity bridge |
| WACC | 8.5% | house estimate | CAPM (beta/rf) | Medium | DCF discount rate |
| Terminal multiple | 29× | house estimate | House rule: 0.85 × the base multiple (shared with the Monte Carlo) | Medium | DCF exit value |
| Terminal growth | 2.5% | house estimate | Long-run GDP+ | Medium | Gordon cross-check (single point, not in the blend) |
| SBC dilution | 2.0%/yr | house estimate | From SBC/revenue | Medium | PWEV, MC, DCF (charged once) |
Research Provenance
| Field | Value |
|---|---|
| Quantitative engine | mch_stock_engine v2.0 |
| Research OS config | ros-1.21.0 |
| Analysis as-of | 2026-10-13 (prices 2026-10-12) |
| Narrative authorship | MCH engine — systematic generation |
| Human review | engine output reviewed at the estate level, not name-by-name |
| Evidence | 7/8 load-bearing inputs sourced; 11/14 mandated claims cited |
| QA | scanned post-emit by the document-QA layer; the publication label (Draft / Research / Decision-level) is stamped on the published page, not authored here |
Load-Bearing Assumptions
DCF: WACC 8.5%, terminal multiple 29×, FY+5 revenue $1B. Triangulation leans 42% on DCF, 30% on PWEV, 18% on the Monte Carlo median, 10% on peer-implied value.
Appendix & audit trail — source log, data provenance, disclosures
Source Log
| Source | Type | Date | Used for | Reference |
|---|---|---|---|---|
| Alpha Vantage — GLOBAL_QUOTE / OVERVIEW | market data | 2026-10-12 | Price, market cap, EV, forward P/E | Alpha Vantage 2026-10-12 |
| MCH engine — trailing 52 weeks of daily bars | derived | 2026-10-12 | 52-week range (intraday high and low over the trailing year of the stock's own daily bars) | trailing 52 weeks of own daily bars (intraday high/low, 2025-10-13 to 2026-10-09, 250 sessions) |
| Company income statement (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-10-12 | Revenue, gross/operating margin, EBIT, interest expense | INCOME_STATEMENT / latest annual |
| Company balance sheet (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-10-12 | Cash, debt, net debt, leases, equity, coverage | BALANCE_SHEET / latest annual |
| Company cash-flow statement (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-10-12 | Operating cash flow, capex, FCF, buybacks, dividends, SBC | CASH_FLOW / latest annual |
| Company earnings releases via Alpha Vantage | reported fact | 2026-10-12 | Reported EPS, surprise history | EARNINGS / quarterly |
| Sell-side consensus via Alpha Vantage | consensus estimate | 2026-10-12 | Forward revenue/EPS consensus, analyst count | EARNINGS_ESTIMATES |
| Earnings calendar via Alpha Vantage | market data | 2026-10-12 | Next earnings date, catalyst timing | EARNINGS_CALENDAR |
| Company guidance | company guidance | 2026-10-12 | FY guided revenue / non-GAAP EPS basis | company guidance / earnings call |
| MCH segment model (from filings & disclosures) | house estimate | 2026-10-12 | Segment revenue and multiple; model margin = gross margin − the calibrated opex ratio (not a reported margin) | company_context (authored, tagged) |
| MCH investment thesis & falsification triggers | house estimate | 2026-10-12 | Thesis, anti-thesis, thesis-break signals | authored §5.3 |
Citation coverage: 11/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.
Data Sources
- Prices, fundamentals, options chain, earnings — Alpha Vantage.
- Company filings (10-K / 10-Q) — SEC filings via EDGAR.
Disclosures & Limitations
This report is for informational and research purposes only. It is not personal financial advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.
- This report is produced by the MCH Analysis quantitative research engine — valuation, scenarios, Monte Carlo and the decision layer are generated systematically from the disclosed inputs and the archetype/industry driver sets, and reviewed rather than written name-by-name. Every figure reconciles to the appendix and every score exposes its inputs.
- No suitability assessment has been performed for any individual.
- Market data may be delayed or inaccurate; figures are as of the analysis date.
- Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
- Forecasts are uncertain; past performance is not indicative of future returns.
- The author or publisher may hold positions in securities mentioned.
- Users should verify information against primary sources (company filings) before acting.
- Investing involves risk of loss; there is no guarantee any target price is achieved.
- Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.
Forecast record. Across 478 scored pre-registered anchors (of 480), the direction implied by our targets has been right 55.2% of the time, above the 50% a coin flip would give, by more than sampling noise at this sample size. Read as probabilities, the targets score worse than a coin flip: a proxy Brier score of 0.253 against 0.25 (lower is better); the probabilities are reconstructed from the price targets, because the engine only began publishing its own on 2026-08-04. By published rating, against each name’s sector ETF (a BUY counts as a hit when it beats it, a SELL when it trails it, a HOLD when it ends within 5 points of it): BUY: 40.0% hits, average alpha +8.9% on 5 scored; HOLD: 30.6%, −2.5% on 418; SELL: 61.4%, −1.1% on 44; STRONG SELL: 50.0%, −0.6% on 6. STRONG BUY: none of its 2 anchors could be scored. Read this page’s price target with that in mind, and see the full accuracy record. Samples are thin and windows short; nothing here is settled in either direction.
General and impersonal investment research. Not personal financial advice. Forecasts, valuations and model outputs are estimates and may be wrong. See Investment Disclaimer.
Disclosures. This report is published by MCH Analysis, a general investment-research publication of MCH Advisory (Pty) Ltd, for informational and quantitative-research purposes only. It is not personal financial advice, legal or tax advice, nor an offer or solicitation to buy or sell any security. Price targets and probabilities are model estimates, not promises; past performance and back-tested or simulated figures do not predict future results. MCH is not a licensed financial services provider or a registered investment adviser; MCH-related persons may hold positions in instruments mentioned (see MCH Interests below).MCH Interests: MCH-related persons and/or associated investment vehicles may hold a financial interest in securities discussed. See Conflicts Policy. Conflicts Policy.Provenance: published 13 October 2026 · Research Standard v4 (decision-level) · US-listed · corrections under the Corrections Policy.This report is general research published identically to the relevant readership and is not a recommendation that any transaction is suitable for you. Ratings, fair values and expected returns are estimates as at 12 October 2026 under methodology version not stated. MCH Interests: MCH-related persons and/or associated investment vehicles may hold a financial interest in securities discussed. See Conflicts Policy. © 2026 MCH Advisory (Pty) Ltd. Redistribution prohibited.